How do GLP-1 medications compare to bariatric surgery for weight loss?

GLP-1 medications produce weight loss comparable to some bariatric procedures but through different mechanisms. Tirzepatide's 20-22% average weight loss approaches lap band results (20-25%) and some gastric sleeve outcomes (25-30%). Gastric bypass typically produces greater weight loss (30-35%) and more durable metabolic improvements. Surgery creates anatomical changes that permanently alter digestion and hunger hormones, while medications require ongoing use. Surgery has higher upfront risks but may offer more permanent solutions. GLP-1s are less invasive, reversible, and don't carry surgical risks. Many patients now try GLP-1s before considering surgery, and some surgeons require medication trial before approving bariatric procedures. For patients with BMIs over 40 or 35+ with significant comorbidities, surgery may still offer superior long-term outcomes.